Head and Neck Cancer (HNC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Head and neck cancer affects nearly 65,000 individuals annually in the United States. Excluding skin and thyroid cancers, over 90% of head and neck malignancies are squamous cell carcinomas (SCCs); the remainder predominantly consists of adenocarcinomas, sarcomas, and lymphomas. A significant majority, exceeding 85%, of patients with head and neck cancer have a history of alcohol consumption, tobacco use, or both. Chronic heavy use of tobacco and alcohol increases the risk of developing squamous cell carcinoma by approximately 40-fold. Other potential risk factors include the use of smokeless tobacco, exposure to sunlight, prior radiation therapy of the head and neck, certain viral infections, poorly fitting dental appliances, chronic candidiasis, and inadequate oral hygiene. In India, the high prevalence of oral cancer is attributed to the chewing of betel quid (paan). For squamous cell carcinoma of the lower lip, prolonged sunlight exposure and tobacco use are the primary etiological factors. The most frequent sites for head and neck cancer include:
• Larynx (encompassing the supraglottis, glottis, and subglottis)
• Oral cavity (including the tongue, floor of the mouth, hard palate, buccal mucosa, and alveolar ridges)
• Oropharynx (comprising the posterior and lateral pharyngeal walls, base of the tongue, tonsils, and soft palate)
Less common sites include the nasopharynx, nasal cavity, paranasal sinuses, hypopharynx, and salivary glands. The tumor’s location and extent influence the clinical manifestations of head and neck cancer. Initial symptoms often include asymptomatic neck masses, painful mucosal ulcerations, visible mucosal lesions (e.g., leukoplakia, erythroplakia), hoarseness, and dysphagia. Diagnosis of head and neck cancer can be physically and emotionally challenging. The disease and its treatments can impair breathing, eating, and communication and alter physical appearance. The impact on psychological and psychosocial well-being can significantly affect quality of life. Prognosis varies widely based on tumor size, primary site, etiology, and regional or distant metastases. Generally, early diagnosis and prompt, appropriate treatment are associated with a more favorable prognosis. Head and neck cancers typically exhibit local invasion before metastasizing to regional cervical lymph nodes. The likelihood of regional lymphatic spread is correlated with tumor size, extent, and aggressiveness, reducing overall survival by nearly 50%. Distant metastases, often to the lungs, generally occur in advanced disease stages, are associated with a significantly reduced survival rate, and are frequently incurable. The primary treatments for head and neck cancer are surgery and radiation therapy, which can be employed alone or in combination with or without chemotherapy. Tumors at different sites may respond similarly to these modalities, with treatment choice influenced by factors such as patient preference and location-specific morbidity. In certain instances, one treatment modality may be superior. For example, surgery is often preferred for early-stage oral cavity cancers due to the risk of mandibular osteoradionecrosis associated with radiation therapy. Endoscopic surgery, increasingly utilized, offers similar or improved cure rates compared to traditional open surgery or radiation, with significantly reduced morbidity. Endoscopic techniques, often employing lasers, are particularly effective for laryngeal surgery and are being explored for selected sinonasal tumors.

Thelansis’s “Head and Neck Cancer (HNC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Head and Neck Cancer (HNC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Head and Neck Cancer (HNC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Head and Neck Cancer (HNC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Head and Neck Cancer (HNC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033